Search results for "host-pathogen interactions"

showing 10 items of 171 documents

Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfected patients

2012

Chronic hepatitis C virus (HCV) infection is the main cause of advanced and end-stage liver disease world-wide, and an important factor of morbidity and mortality in Human Immunodeficiency virus-1 (HIV-1) co-infected individuals. Whereas the genetic variability of HCV has been studied extensively in monoinfected patients, comprehensive analyses of both patient and virus characteristics are still scarce in HCV/HIV co-infection. In order to find correlates for liver damage, we sought to analyze demographic, epidemiological and clinical features of HCV/HIV co-infected patients along with the genetic makeup of HCV (viral subtypes and lineage studied by nucleotide sequencing and phylogenetic ana…

AdultLiver CirrhosisMaleMicrobiology (medical)medicine.medical_specialtyHepatitis C virusHIV InfectionsHepacivirusViral Nonstructural ProteinsBiologymedicine.disease_causeModels BiologicalMicrobiologyViruschemistry.chemical_compoundLiver diseaseFibrosisEpidemiologyGeneticsmedicineHumansGenetic variabilityMolecular BiologyNS5BPhylogenyEcology Evolution Behavior and SystematicsRetrospective StudiesPhylogenetic treeCoinfectionvirus diseasesHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyLinear ModelsFemaleInfection, Genetics and Evolution
researchProduct

The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects

2017

Altered interactions between the gut mucosa and bacteria during HIV infection seem to contribute to chronic immune dysfunction. A deeper understanding of how nutritional interventions could ameliorate gut dysbiosis is needed. Forty-four subjects, including 12 HIV+ viremic untreated (VU) patients, 23 antiretroviral therapy-treated (ART(+)) virally suppressed patients (15 immunological responders and 8 non-responders) and 9 HIV- controls (HIV-), were blindly randomized to receive either prebiotics (scGOS/lcFOS/glutamine) or placebo (34/10) over 6 weeks in this pilot study. We assessed fecal microbiota composition using deep 16S rRNA gene sequencing and several immunological and genetic marker…

AdultMale0301 basic medicine030106 microbiologyImmunologyHIV InfectionsInflammationButyrateBiologyGut floraMicrobiologyFeces03 medical and health sciencesIntestinal mucosaImmunityRNA Ribosomal 16SmedicineHumansImmunology and AllergyIntestinal MucosaBacteriaImmunityMiddle AgedPlacebo Effectmedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeGlutamineButyratesPrebiotics030104 developmental biologyMucosal immunologyDietary SupplementsHost-Pathogen InteractionsImmunologyHIV-1DysbiosisFemalemedicine.symptomDysbiosisMucosal Immunology
researchProduct

Diabetes mellitus association with coronavirus disease 2019 ( COVID ‐19) severity and mortality: A pooled analysis

2020

Highlights There are ~ 2-fold increased odds of severe coronavirus disease 2019 (COVID-19) and a ~ 2-fold increased risk of odds of mortality in patients with history of diabetes mellitus compared to those without diabetes mellitus. Patients with a history of diabetes mellitus should be closely monitored if they get infected with COVID-19. Results of meta-analysis showing association of diabetes mellitus with severity (Panel A) of disease and mortality (Panel B) in coronavirus disease 2019 (COVID-19) patients.

AdultMalemedicine.medical_specialtyTime FactorsAdolescentendocrine system diseasesEndocrinology Diabetes and MetabolismPneumonia Viralcoronavirus030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologymedicine.disease_causeRisk AssessmentSeverity of Illness IndexCOVID-19 coronavirus diabetes mellitusBetacoronavirusYoung Adult03 medical and health sciences0302 clinical medicineCOVID‐19Risk FactorsCause of DeathInternal medicineDiabetes mellitusPandemicSeverity of illnessResearch LetterHumansMedicineYoung adultPandemicsAgedCoronavirusCause of deathAged 80 and overSARS-CoV-2business.industryCOVID-19Middle AgedPrognosismedicine.diseaseResearch LettersHost-Pathogen Interactionsdiabetes mellitusFemaleCoronavirus InfectionsbusinessRisk assessmentJournal of Diabetes
researchProduct

Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immuno…

2012

Abstract Background Predictors of sustained virological response (SVR) to antiviral therapy post-liver transplantation (LT) for chronic hepatitis C are needed. In non-transplanted patients, viral kinetics can predict SVR. Objectives To determine the early viral kinetics in LT recipients with different immunosuppression (tacrolimus – Tac- vs. cyclosporine – CsA-) during treatment with peg-IFN + RBV. Study design Prospective pilot study in HCV-1b infected patients: (LT CsA n = 8; Tac n = 8; non-LT n = 4), treated with IFN α-2a vs. α-2b (180 μg or 1.5 μg/kg, respectively) once weekly plus weight-based RBV. Median CsA or Tac baseline trough levels were 141 and 7.70 ng/mL, respectively. HCV-RNA …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPilot ProjectsHepacivirusInterferon alpha-2Biologymedicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene GlycolsImmunocompromised Hostchemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesAgedRibavirinInterferon-alphaImmunosuppressionHepatitis C ChronicMiddle AgedViral LoadViral kineticsRecombinant ProteinsTacrolimusLiver TransplantationTransplantationKineticsTreatment OutcomeInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyFemaleViral loadmedicine.drugJournal of Clinical Virology
researchProduct

Noroviral P-Particles as an In Vitro Model to Assess the Interactions of Noroviruses with Probiotics

2014

Noroviruses (NoVs) are the main etiologic agents of acute epidemic gastroenteritis and probiotic bacteria have been reported to exert a positive effect on viral diarrhea. The protruding (P) domain from NoVs VP1 capsid protein has the ability to assemble into the so-called P-particles, which retain the binding ability to host receptors. We purified the P-domains from NoVs genotypes GI.1 and GII.4 as 6X(His)-tagged proteins and determined that, similar to native domains, they were structured into P-particles that were functional in the recognition of the specific glycoconjugated receptors, as established by surface plasmon resonance experiments. We showed that several lactic acid bacteria (pr…

Applied Microbiologylcsh:Medicinemedicine.disease_causeBiochemistrylaw.inventionProbioticGastrointestinal tractlawLactobacillusGram Negativelcsh:ScienceReceptorMultidisciplinarybiologyBacterial PathogensGastroenteritisHost-Pathogen InteractionLacticaseibacillus caseiHost-Pathogen InteractionsMedicineReceptors VirusBacterial and Foodborne IllnessHT29 CellsGram negative bacteriaResearch ArticleProtein BindingLactobacillus caseiGram-negative bacteriaVirus AttachmentGastroenterology and HepatologyMicrobiologyMicrobiologyVirologyViruslike ParticlesEscherichia colimedicineHumansProtein InteractionsBiologyEscherichia coliProbioticsNoroviruslcsh:RHealth careProteinsCell bindingBacteriologySurface Plasmon Resonancebiology.organism_classificationVirologyIn vitroLactobacillusEnterocytesCapsid Proteinslcsh:QBacteria
researchProduct

Experimental virus evolution reveals a role of plant microtubule dynamics and TORTIFOLIA1/SPIRAL2 in RNA trafficking.

2014

1 tabla y 2 figuras

ArabidopsisPlant ScienceMicrotubulesRNA Transport//purl.org/becyt/ford/1 [https]INFECTIONTobacco mosaic virusTOBACCO-MOSAIC-VIRUSMovement proteinCytoskeletonCytoskeletonGeneticsCoat proteinMultidisciplinaryTRANSGENIC PLANTSQREXPERIMENTAL EVOLUTIONARABIDOPSISBiological Evolution3. Good healthCell biologyMacromolecular assemblyTobacco Mosaic VirusMICROTUBULESMedical MicrobiologyTobamovirusesViral Pathogensdynamic plasticityHost-Pathogen InteractionsMedicineTobacco mosaic viruscortical microtubuleCellular Structures and OrganellesCortical microtubuleARABIDOPSIS CORTICAL MICROTUBULESCell wallsMicrotubule-Associated ProteinsCIENCIAS NATURALES Y EXACTASResearch ArticleEvolutionary ProcessesSciencePlant Cell BiologyPlant PathogensORGANIZATIONBiologyMicrobiologyPlant Viral PathogensCiencias BiológicasMOVEMENT PROTEINComplexesMicrotubuleEvolutionary Adaptation//purl.org/becyt/ford/1.6 [https]Microbial PathogensPlant DiseasesEvolutionary BiologyArabidopsis ProteinsBotánicaRNABiology and Life SciencesCell BiologyPlant PathologyTMVCytoplasmMutationRNAVirologíaHELICAL GROWTHPloS one
researchProduct

Invasion Ability and Disease Dynamics of Environmentally Growing Opportunistic Pathogens under Outside-Host Competition

2014

Most theories of the evolution of virulence concentrate on obligatory host-pathogen relationship. Yet, many pathogens replicate in the environment outside-host where they compete with non-pathogenic forms. Thus, replication and competition in the outside-host environment may have profound influence on the evolution of virulence and disease dynamics. These environmentally growing opportunistic pathogens are also a logical step towards obligatory pathogenicity. Efficient treatment methods against these diseases, such as columnaris disease in fishes, are lacking because of their opportunist nature. We present a novel epidemiological model in which replication and competition in the outside-hos…

Bacterial Diseases0106 biological sciencesPopulation ModelingDisease01 natural sciencesTheoretical EcologyMedicine and Health SciencesPathogenPOPULATIONmedia_common0303 health scienceseducation.field_of_studyPREDATIONMultidisciplinaryEcologyTransmission (medicine)EcologySimulation and ModelingQRCHANNEL CATFISHEVOLUTIONARY DYNAMICSCOMMUNITYInfectious DiseasesHost-Pathogen Interactions1181 Ecology evolutionary biologyMedicineAlgorithmsResearch ArticleTRANSMISSIONSciencemedia_common.quotation_subjecteducationPopulationVirulenceOpportunistic InfectionsBiologyResearch and Analysis Methods010603 evolutionary biologyCompetition (biology)03 medical and health sciences14. Life underwaterParasite EvolutioneducationEvolutionary dynamicsta413030304 developmental biologyEvolutionary BiologyMathematical ModelingSTABILITYMORTALITYEcology and Environmental SciencesBiology and Life SciencesComputational BiologyFLAVOBACTERIUM-COLUMNAREOutbreakModels TheoreticalEmerging Infectious DiseasesEvolutionary Ecologyta1181VIRULENCEParasitologyInfectious Disease ModelingPLoS ONE
researchProduct

Type-IIA secreted phospholipase A2 is an endogenous antibiotic-like protein of the host.

2010

International audience; Type-IIA secreted phospholipase A(2) (sPLA(2)-IIA) has been proposed to play a role in the development of inflammatory diseases. It has been shown to release arachidonic acid, the precursor of proinflammatory eicosanoids, to hydrolyze phospholipids of pulmonary surfactant, and to bind to specific receptors located on cell surface membranes. However, the most established biological role of sPLA(2)-IIA is related to its potent bactericidal property in particular toward Gram-positive bacteria. This enzyme is present in animal and human biological fluids at concentrations sufficient to kill bacteria. Human recombinant sPLA(2)-IIA is able to kill Gram-positive bacteria at…

Bacterial Toxinsmedicine.disease_causeGroup II Phospholipases A2BiochemistryMicrobiologyAnthraxMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemPhospholipase A2PhosphatidylcholinemedicineAnimalsHumansEscherichia coli030304 developmental biologyAntigens Bacterial0303 health sciencesPhospholipase AArachidonic AcidbiologyDrug Resistance MicrobialPathogenic bacteriaGeneral Medicinebiology.organism_classificationAnti-Bacterial Agents3. Good healthBacillus anthracisBiochemistrychemistryBacillus anthracisHost-Pathogen Interactionsbiology.protein[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/VaccinologyBacteria030215 immunology
researchProduct

Host–virus evolutionary dynamics with specialist and generalist infection strategies: Bifurcations, bistability, and chaos

2019

In this work, we have investigated the evolutionary dynamics of a generalist pathogen, e.g., a virus population, that evolves toward specialization in an environment with multiple host types. We have particularly explored under which conditions generalist viral strains may rise in frequency and coexist with specialist strains or even dominate the population. By means of a nonlinear mathematical model and bifurcation analysis, we have determined the theoretical conditions for stability of nine identified equilibria and provided biological interpretation in terms of the infection rates for the viral specialist and generalist strains. By means of a stability diagram, we identified stable fixed…

BistabilityPopulationGeneral Physics and AstronomyDynamical Systems (math.DS)Fixed pointParameter spaceBiologyGeneralist and specialist speciesModels Biological01 natural sciencesStability (probability)010305 fluids & plasmas0103 physical sciencesFOS: MathematicsHumansQuantitative Biology::Populations and EvolutionComputer SimulationMathematics - Dynamical SystemsQuantitative Biology - Populations and Evolution010306 general physicsEvolutionary dynamicseducationMathematical Physicseducation.field_of_studyApplied MathematicsDegenerate energy levelsPopulations and Evolution (q-bio.PE)Statistical and Nonlinear Physics3. Good healthNonlinear DynamicsEvolutionary biologyFOS: Biological sciencesHost-Pathogen InteractionsVirusesVirus Physiological Phenomena
researchProduct

HCV genotype 5: an orphan virus

2013

HCV genotype 5 (HCV-5) is the least known HCV genotype. It is found mainly in South Africa and in restricted areas of Belgium, Spain, France, Syria and Greece. Sporadic cases are reported worldwide. The main modes of transmission are blood transfusion and iatrogenic causes. Little is known about its origin, but various studies have elucidated its spread worldwide. In endemic areas, patients infected with HCV-5 are on average older and have a higher viral load and more advanced fibrosis than those infected with non-HCV-5 genotypes. The current standard of care for HCV-5 chronic infection is 48 weeks of dual therapy with pegylated interferon plus ribavirin. ‘Favourable’ Il28B polymorphisms a…

Blood transfusionGenotypemedicine.medical_treatmentHepacivirusAntiviral Agentschemistry.chemical_compoundPegylated interferonGenotypemedicinePrevalenceHumansPharmacology (medical)PharmacologyTransmission (medicine)business.industryRibavirinvirus diseasesHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseasesChronic infectionInfectious DiseasesTreatment OutcomechemistryImmunologyHost-Pathogen InteractionsbusinessViral loadmedicine.drug
researchProduct